Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 46, Issue 4, 2005, Pages 509-516

  Stasi, Roberto ^a   Amadori, Sergio ^b   Newland, Adrian C ^c   Provan, Drew ^c  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apoptosis; Infliximab; Myelodysplastic syndromes; Tumor necrosis factor

Indexed keywords

AMIFOSTINE; CIPROFLOXACIN; DEXAMETHASONE; ETANERCEPT; INFLIXIMAB; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG USE; ERYTHROCYTE TRANSFUSION; FACE EDEMA; FOLLOW UP; HEMATOPOIESIS; HUMAN; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; HUMANS; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17844396018     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400027829     Document Type: Review

References (53)

1. Hellstrom-Lindberg E, Willman C, Barrett AJ, Saunthararajah Y. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Prog) 2000;110-132.
2. Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Prog) 2003;176-199.
3. Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol 2003;33:153-160.
4. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199-212.
5. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Sherry V, Parcharidou A. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-276.
6. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996;20:891-900.
7. Mundle SD, Mativi BY, Bagai K, Feldman G, Cheema P, Gautam U, Reza S, Cartlidge JD, Venugopal P, Shetty V, et al. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. Int J Hematol 1999;70:83-90.
8. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P, Gregory SA, Raza A. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999;140:201-207.
9. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-259.
10. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.
11. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-1602.
12. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359: 1187-1193.
13. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-1847.
14. Reimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 2003;325:75-92.
15. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96:3932-3938.
16. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997;21:415-425.
17. Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, Zikos P, Orphanos V, Zoumbos NC. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia 1999;13:1554-1563.
18. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of proversus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998;103:1075-1082.
19. Ali A, Mundle SD, Ragasa D, Reza S, Shetty V, Mativi BY, Cartlidge JD, Azharuddin M, Qawi H, Dar S, Raza A. Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res 1999;8:343-356.
20. Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998;91:1235-1242.
21. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34 + human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183-3190.
22. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-6965.
23. De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E, Riccioni R, Felli N, Samoggia P, Peschle C. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999;93:796-803.
24. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995;86:883-889.
25. Gersuk GM, Lee JW, Beckham CA, Anderson J, Deeg HJ. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 1996;88:1122-1123.
26. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998;12:486-492.
27. Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, Melle J, Lacombe C, Gisselbrecht S, Mayeux P, Dreyfus F. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 1999;106:464-473.
28. Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, Schultz C, Knapp DJ, Kratzke RA. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999;13:44-53.
29. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997;11:839-845.
30. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;88:4275-4287.
31. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176-188.
32. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11:2049-2054.
33. Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34 + myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997;99:625-631.
34. Sawanobori M, Yamaguchi S, Hasegawa M, Inoue M, Suzuki K, Kamiyama R, Hirokawa K, Kitagawa M. Expression of TNF receptors and related signalling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003;27:583-591.
35. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-1401.
36. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-1434.
37. Stasi R, Amadori S. The role of angiogenesis in hematologic malignancies. J Hematother Stem Cell Res 2002;11:49-68.
38. Arimura K, Arima N, Matsushita K, Ohtsubo H, Fujiwara H, Kukita T, Ozaki A, Hagiwara T, Hamada H, Yoshino K, Tei C. Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. Eur J Haematol 2004;73:17-24.
39. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555-557.
40. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733.
41. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. Metalloproteinase mediated release of human Fas ligand. J Exp Med 1995;182:1777-1783.
42. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000;95:1580-1587.
43. Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, Zeigler Z, Shadduck R. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am J Clin Oncol 1995;18:189-193.
44. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996;81:219-223.
45. Raza A, Meyer P, Dun D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-965.
46. Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K, Dar S, York A, Gezer S, Venugopal P, Raza A. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001;115:881-894.
47. Maciejewski JP, Risitano AM, Sloand EM, Wisch L, Geller N, Barrett JA, Young NS, Ristiano AM. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002;117:119-126.
48. Deeg HJ, Gotlib, J, Beckham C, Dugan K, Holmberg L, Schubert M, Appelbaum F, Greenberg P. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002;16:162-164.
49. Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001;13:164-169.
50. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003;102:2768-2776.
51. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649-654.
52. Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, Billmeier J, Alvi MI, Mumtaz M, Gezer S, et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 2004;45:2099-2104.
53. Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Bianchi M, Parma A, Pagano A. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 1997;19:197-201.